To investigate whether tumor cell-intrinsic STING activity can influence antitumor responses to STING agonist therapy, we injected STINGgt/gt mice subcutaneously with B16-ISG or B16-ISG-STINGKO murine melanoma cells and treated them intratumorally with either the STING agonist ADU-S100 or PBS as vehicle control (Supplementary Fig. 1a). The gene discussed is STING1; the disease is neoplasm.